The Pharma Data

NOVEMBER 5, 2020

REGN-COV2 trial in the COVID-19 outpatient setting met primary and key secondary endpoints. FDA accepted for priority review Libtayo ® (cemiplimab-rwlc) for both advanced non-small cell lung cancer and basal cell carcinoma. FDA approved Inmazeb for Ebola ( Zaire ebolavirus). Regeneron Pharmaceuticals, Inc. Schleifer , M.D., Total revenues (4). $.

Sales 52

Sales Production Manufacturing Antibody 52

The Pharma Data

DECEMBER 5, 2020

“As these data continue to mature, we look forward to assessing whether responses will further deepen and remain durable with ongoing REGN5458 treatment.” “As these data continue to mature, we look forward to assessing whether responses will further deepen and remain durable with ongoing REGN5458 treatment.”

Antibody 40

Antibody Production Trials Medicine 40

The Pharma Data

OCTOBER 28, 2020

Based on this finding, Regeneron is reviewing potential changes to dosing in the ongoing outpatient clinical trial given the current limited supply of REGN-COV2. Regeneron has shared these results with the U.S. Regeneron Pharmaceuticals, Inc. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron. There was a 1.08

Antibody 40

Antibody Trials Production Clinical Trials 40

World of DTC Marketing

OCTOBER 16, 2020

Marketers understand that changing the behavior, and beliefs, of consumers, is hard. When it comes to a potentially new COVID-19 vaccine changing the behavior of people is going to take a multi-touchpoint assault. Insurers should mandate that customers get vaccinated but it has to be with facts, not threats.

Vaccination 260

Vaccination Vaccine Marketing Clinical Trials 260

The Pharma Data

MAY 4, 2021

Billion, Revenues Grew 8% Operationally Including a Negative 5% Impact from Pricing. Each of these accomplishments further demonstrates our commitment to Pfizer’s purpose: Breakthroughs that change patients’ lives.”. First-Quarter 2021 Revenues of $14.6 Billion, Reflecting 42% Operational Growth; Excluding Revenues for BNT162b2 of $3.5

Vaccination 40

Vaccination Vaccine Production Sales 40

XTalks

SEPTEMBER 14, 2020

Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. The price of that prize is incalculable.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92